肿瘤细胞治疗研究
FRONTIER PAPERS
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
这些发现支持抗 BCMA/GPRC5D 双特异性 CAR T 细胞在伴骨外 EMD 的复发/难治性多发性骨髓瘤（RRMM）患者中诱导了高缓解率，且安全性可控。
Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-ar
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 t
这些发现共同凸显了针对侵袭性多发性骨髓瘤患者、尤其是伴髓外疾病患者的 BCMA/GPRC5D 双靶向 CAR T 细胞疗法的潜在治疗策略，并支持在更大规模的多中心临床研究中进一步探索和验证的必要性。
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
抗BCMA/GPRC5D双特异性CAR T细胞在复发或难治性多发性骨髓瘤患者中显示出良好的安全性特征和令人鼓舞的活性。
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
我们的研究表明，双特异性 BC19 CAR T 细胞治疗 R/R MM 患者可行、安全且有效。
Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma.
这些发现表明，以FcRH5为靶点的CAR-T细胞可能代表MM的一种有前景的治疗途径。
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
我们的结果证实，BCMA-CD38 CAR-T细胞疗法治疗R/R MM患者是可行的，具有高缓解率、低复发率和可控的CRS，将成为R/R MM一种有前景的治疗选择。
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
双特异性BM38 CAR-T在RRMM患者中可行、安全且显著有效。
Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma.
靶向B细胞成熟抗原（BCMA）的嵌合抗原受体（CAR）-T细胞疗法已显示出显著疗效，被认为是治疗复发或难治性多发性骨髓瘤（R/R MM）的理想靶点。
MEMBER ACCOUNT
登录成功会直接打开下一页。
